SA516371223B1 - لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية - Google Patents

لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية Download PDF

Info

Publication number
SA516371223B1
SA516371223B1 SA516371223A SA516371223A SA516371223B1 SA 516371223 B1 SA516371223 B1 SA 516371223B1 SA 516371223 A SA516371223 A SA 516371223A SA 516371223 A SA516371223 A SA 516371223A SA 516371223 B1 SA516371223 B1 SA 516371223B1
Authority
SA
Saudi Arabia
Prior art keywords
mers
sequence
cov
ser
antigen
Prior art date
Application number
SA516371223A
Other languages
Arabic (ar)
English (en)
Inventor
بي. وينير ديفيد
موثوماني كاروبيا
واي. سارديساي نيرانجان
Original Assignee
انوفيو فارماسيوتيكالز، إنك.
ذي ترستيز أوف ذي يونيفيرستي أوف بنسلفانيا
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by انوفيو فارماسيوتيكالز، إنك., ذي ترستيز أوف ذي يونيفيرستي أوف بنسلفانيا filed Critical انوفيو فارماسيوتيكالز، إنك.
Publication of SA516371223B1 publication Critical patent/SA516371223B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SA516371223A 2013-11-29 2016-05-29 لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية SA516371223B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29

Publications (1)

Publication Number Publication Date
SA516371223B1 true SA516371223B1 (ar) 2023-01-31

Family

ID=53199622

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516371223A SA516371223B1 (ar) 2013-11-29 2016-05-29 لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية

Country Status (10)

Country Link
US (5) US10016497B2 (https=)
EP (1) EP3074051A4 (https=)
JP (1) JP6412131B2 (https=)
KR (2) KR20160091350A (https=)
CN (2) CN112057613A (https=)
AU (1) AU2014354797C1 (https=)
CA (1) CA2932055A1 (https=)
IL (3) IL276210B2 (https=)
SA (1) SA516371223B1 (https=)
WO (1) WO2015081155A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9889194B2 (en) 2013-03-01 2018-02-13 New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
KR20160091350A (ko) * 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
US11058779B2 (en) 2015-09-08 2021-07-13 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
TW201729835A (zh) * 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
WO2018097603A2 (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
CN115867349A (zh) 2020-02-25 2023-03-28 艾诺奥医药品有限公司 针对冠状病毒的疫苗和使用方法
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
KR102756774B1 (ko) * 2020-05-08 2025-01-21 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도
JP2023525552A (ja) * 2020-05-12 2023-06-16 グレフェックス, インコーポレイテッド ワクチン抗原としてのコロナウイルススパイクタンパク質の操作、その設計及び使用
US20230210981A1 (en) * 2020-06-09 2023-07-06 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
WO2022011332A2 (en) * 2020-07-10 2022-01-13 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
WO2022020604A1 (en) * 2020-07-22 2022-01-27 Greffex, Inc. Multivalent beta-coronavirus vaccines, their design and uses
JPWO2022025029A1 (https=) * 2020-07-27 2022-02-03
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
WO2022046737A1 (en) * 2020-08-25 2022-03-03 The Wistar Institute Of Anatomy And Biology Intradermal mers-cov vaccine
WO2022051816A1 (en) * 2020-09-10 2022-03-17 The Council Of The Queensland Institute Of Medical Research Methods of determining immune response
EP4210724A4 (en) * 2020-09-11 2024-10-02 Memgen, Inc. INCREASING IMMUNITY WITH CHIMERIC CD40 LIGAND AND CORONAVIRUS VACCINE
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
EP1102608A4 (en) 1998-07-13 2008-09-17 Genetronics Inc METHOD AND APPARATUS FOR THE ELECTRICALLY SUPPORTED SURFACE APPLICATION OF COSMETIC MEANS
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
WO2000067837A1 (en) 1999-05-10 2000-11-16 Gentronics, Inc. Method of electroporation-enhanced delivery of active agents
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
JP2007502612A (ja) * 2003-08-18 2007-02-15 アムステルダム インスティチュ−ト オブ ヴァイラル ゲノミックス ベー.フェー. コロナウイルス、核酸、蛋白質、ならびにワクチンの生成方法、薬剤および診断
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
CA2567116A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
AU2009279456B2 (en) * 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
JP5940554B2 (ja) * 2010-12-09 2016-06-29 アンスティテュ・パストゥールInstitut Pasteur 高収量の組換えタンパク質発現を得るためのmgmtに基づく方法
MX349562B (es) 2011-12-09 2017-08-02 Pasteur Institut Ensayo de inmuno deteccion multiplex.
EP2876161B1 (en) * 2012-07-23 2018-12-05 The Institute of Biological Resources Vaccine
KR102399854B1 (ko) 2013-09-19 2022-05-19 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜERS-CoV) 조성물 및 방법
KR20160091350A (ko) * 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Also Published As

Publication number Publication date
CN105939730A (zh) 2016-09-14
IL276210B2 (en) 2024-01-01
US20190022213A1 (en) 2019-01-24
WO2015081155A1 (en) 2015-06-04
IL245903A0 (en) 2016-07-31
US11801298B2 (en) 2023-10-31
AU2014354797A1 (en) 2016-07-07
US20200222527A1 (en) 2020-07-16
AU2014354797C1 (en) 2018-02-01
IL276210A (en) 2020-09-30
US11135284B2 (en) 2021-10-05
CN105939730B (zh) 2020-09-11
US10016497B2 (en) 2018-07-10
CA2932055A1 (en) 2015-06-04
EP3074051A1 (en) 2016-10-05
US20170258893A1 (en) 2017-09-14
JP6412131B2 (ja) 2018-10-24
JP2016539946A (ja) 2016-12-22
US10548971B2 (en) 2020-02-04
AU2014354797B2 (en) 2017-10-26
IL276210B1 (en) 2023-09-01
US20240123056A1 (en) 2024-04-18
IL245903B (en) 2020-08-31
CN112057613A (zh) 2020-12-11
KR20160091350A (ko) 2016-08-02
US20210401972A1 (en) 2021-12-30
IL305392A (en) 2023-10-01
KR20230122181A (ko) 2023-08-22
EP3074051A4 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
SA516371223B1 (ar) لقاح لفيروس كورونا المسبب لمتلازمة الشرق الأوسط التنفسية
Martinez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
Singh et al. Foot-and-mouth disease virus: immunobiology, advances in vaccines and vaccination strategies addressing vaccine failures—an Indian perspective
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
Hsieh et al. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
UA126848C2 (uk) Філовірусна вакцина на основі рекомбінантного модифікованого вірусу вісповакцини анкара (mva)
CN109152826A (zh) 新抗寨卡病毒疫苗
WO2021262672A1 (en) Sars-cov-2 rbd constructs
Wang et al. Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice
Zeng et al. Exploring the potential of cytomegalovirus-based vectors: a review
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
Jeong et al. Immune responses of a novel bi-cistronic SARS-CoV-2 DNA vaccine following intradermal immunization with suction delivery
Zhao et al. Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
Shchelkunov et al. Enhancing the immunogenicity of vaccinia virus
Chi et al. Inactivated rabies virus vectored MERS-coronavirus vaccine induces protective immunity in mice, camels, and alpacas
Di et al. The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice
Salleh Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development
Ren et al. Optimizing encephalomyocarditis virus VP1 protein assembly on pseudorabies virus envelope via US9 protein anchoring
Xu et al. Generation and evaluation of recombinant baculovirus coexpressing gp5 and m proteins of porcine reproductive and respiratory syndrome virus type 1
Cui et al. Enhancing immune responses against SARS-CoV-2 variants in aged mice with INDUK: A chimeric DNA vaccine encoding the spike S1-TM subunits
Starodubova et al. Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging
Liu et al. Immunogenicity of recombinant BCGs expressing predicted antigenic epitopes of bovine viral diarrhea virus E2 gene
Basingab et al. Insight to SARS-CoV-2 Vaccines Based on Virus Structure and Properties
WO2025083402A1 (en) Coronavirus vaccines
Barbosa et al. A Multi-Epitope Recombinant Vaccine Candidate Against Bovine Alphaherpesvirus 1 and 5 Elicits Robust Immune Responses in Mice and Rabbits